沃森生物：子公司冻干带状疱疹病毒mRNA疫苗临床试验申请获得受理。

Group 1 - The core point of the article is that Watson Bio's subsidiary has had its clinical trial application for a freeze-dried herpes zoster virus mRNA vaccine accepted [1] Group 2 - The acceptance of the clinical trial application indicates progress in the development of innovative vaccine technology within the company [1] - This development could potentially enhance the company's position in the biopharmaceutical industry, particularly in the vaccine segment [1] - The mRNA vaccine technology is gaining traction globally, which may lead to increased interest and investment in similar projects [1]